Navigation Links
ViroPharma To Release 2013 Second Quarter Financial Results On August 1, 2013
Date:7/25/2013

EXTON, Pa., July 25, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2013 are expected to be released on Thursday, August 1, 2013 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2013 second quarter financial results along with other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until August 15, 2013.  To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma To Participate In Two May Healthcare Investor Conferences
2. ViroPharma Announces First Quarter 2013 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
4. ViroPharma to Participate in Two December Healthcare Investor Conferences
5. New Vacuum Catalog, UHV Compatible Motorized Positioners, Linear Stages, Rotary Stages, Beamline Instrumentation Released by PI miCos
6. NSG Precision Cells Announces the Release of High Quality Calibration Standards for UV-VIS Spectrophotometers
7. NEBA Health Releases Key Study Results for the first FDA approved brain wave test to help clinicians assess ADHD in children and adolescents
8. NSG Has Just Released Its NIST 930e Photometric Accuracy Standard Kit for Spectrometer Calibration and It's Changing the Spectroscopy World
9. Bend Research Presents Drug Delivery Advancements at Controlled Release Society Annual Meeting
10. Chemical Publishing Company to Release New Title Boiler Water Treatment Principles and Practice: Charts and Notes for Field Use
11. Patheon to Showcase Controlled Release Capabilities at CRS 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... ... 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL will be ... series, “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” As the ... Research and Therapy Act, Okyanos maintains a mission to help “no-option” patients and ...
(Date:3/22/2017)... ... March 21, 2017 , ... Aqua Design Innovations ... goal and raising over $30,000 in the first 40 minutes of crowdfunding. EcoQube ... herbs fast, easy, and affordably, anywhere. , “Simply add fertilized water and in ...
(Date:3/22/2017)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... March 21, ... ... of regional blood flow and tissue oxygenation, is being explored as a way to ... Functional near-infrared spectroscopy study on tonic pain activation by cold pressor test ,” published ...
Breaking Biology Technology:
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/27/2017)... Strategic Cyber Ventures , the industry,s first cybersecurity focused ... investment in  Polarity , the first commercial human memory-augmentation ... and is led by cybersecurity veterans Tom Kellermann ... , also a longtime cybersecurity veteran and founder of ... round of funding. This new funding will be used ...
Breaking Biology News(10 mins):